Research Synthesis: Telomere Cancer Effects

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Attribute each outcome-class finding to specific cited sources by name and year at the finding level, not just at the aggregate count level, so that readers can trace mapped claims to evidence.
2. Reconcile the '0 cross-study disagreements' framing with the actual bundle content: Chen 2023, Wan 2023, Song 2022, Andreikos 2024, and Jesus 2012 report directional findings (predominantly that longer telomeres are associated with increased risk of multiple cancers) that disagree with sources reporting null or protective associations. These must be surfaced in the Tensions and Gaps section, not smoothed into a tiered profile.
3. Resolve the source-list mismatch: either add the eight author-year citations referenced in Limitations (Brouwers 2016, Alhareeri 2020, Liang 2024, Breitling 2016, Mervic 2024, Jaeger 2024, Jesus 2012, Nair-Shalliker 2021) to the bundle with full metadata, or rewrite Limitations to use only bundle sources.
4. Clarify whether the Frailty 'positive signal' refers to Jaeger 2024 (Astragalus supplement, TL outcome, not frailty) and, if so, reassign that source to the appropriate outcome class or add a frailty-outcome source.
5. Remove or correct the '0 cross-study disagreements' claim from the Abstract and Scope sections to match the Tensions and Gaps section, which acknowledges unresolved cross-source tensions.
6. Expand the Tensions and Gaps section to name the specific sources that disagree (e.g. Chen 2023 longer-LTL-increases-cancer-risk vs. Andreikos 2024 short-TL-increases-HNC-risk) and explain why these are not adjudicated.

Major issues

• The Findings Map presents outcome-class aggregate counts (e.g. 'n=17; claims=471') but does not attribute any specific directional claim to a specific cited source at the finding level; readers cannot trace any mapped statement back to a particular paper in the bundle.
• Several sources in the bundle directly contradict the claim of '0 cross-study disagreements' and the dominant null/adjacent framing. Chen 2023 reports robust evidence that longer LTL increases risk of 24 neoplasms; Wan 2023 reports LTL increases prostate cancer risk (OR ~1.37-1.72); Song 2022 reports TL shortening reduces skin cancer risk; Andreikos 2024 reports short TL increases HNC risk (OR 1.38); Jesus 2012 reports telomerase gene therapy increased lifespan without increasing cancer. The evidence map suppresses these substantive disagreements behind a 'tiered evidence profile' frame.
• The 24 sources cited in the manuscript do not match the 24 listed in the source bundle, and the Search Summary references author-year citations (Brouwers 2016, Alhareeri 2020, Liang 2024, Breitling 2016, Mervic 2024, Jaeger 2024, Jesus 2012, Nair-Shalliker 2021) that are not present in the submitted source bundle, undermining auditability.
• The Frailty 'positive signal in 1/1 sources' finding is not attributable to a specific source in the bundle; Jaeger 2024 (the only candidate frailty-adjacent source, an Astragalus supplement RCT) is a supplement trial, not a frailty intervention, and its outcome is telomere lengthening rather than a validated frailty endpoint.
• The Abstract claims '0 cross-study disagreements' while the Limitations section implicitly acknowledges mechanistic-vs-clinical tensions and the Tensions and Gaps section calls for resolving '0 disagreement(s)'; this internal contradiction is a coherence defect.

Minor issues

• Outcome class labels are heterogeneous (Frailty has 1 source, Dosing/PK has 1, Longevity has 1) and the single-source slices are presented with the same table structure as multi-source slices without flagging that they cannot support class-level inferences.
• Several included sources are tangentially related to a 'telomere cancer effects' map (e.g. Benetos 2017 on atherosclerosis, Ahiawodzi 2020 on NEFAs, Lu 2019 on DNAmTL methodology, Breitling 2016 on epigenetic age acceleration) but are placed in the dominant Contextual Adjacent Evidence bucket without explaining their relevance.
• The Sobolewski 2026 source is dated 2026 in the bundle, which is implausible given the stated retrieval window of 2026-06-15 and should be verified.
• Search Summary lists nine topic-anchored queries that are generic (e.g. 'cancer aging') and would return a large unrelated literature; no query strings are reported with operators or field tags, weakening auditability of the search boundary.
• The abstract's framing of 'bounded geroscience hypothesis' is itself a synthesis conclusion that is not clearly grounded in any specific mapped finding.

Reviewer note

Evidence-map review of 'Research Synthesis: Telomere Cancer Effects.' The manuscript presents itself as a bounded landscape with auditable scope, but several integrity issues push it out of the accept tier. (1) Source attribution is at the outcome-class aggregate level (n=17, n=2, etc.) rather than at the finding level, so no mapped directional statement can be traced to a specific cited paper in the bundle. This is the central defect for an evidence map. (2) The Abstract and Scope assert '0 cross-study disagreements,' but the bundle itself contains papers with clear directional disagreement: Chen 2023 (longer LTL increases 24 neoplasms), Wan 2023 (long LTL increases PCa), Song 2022 (TL shortening reduces skin cancer), Andreikos 2024 (short TL increases HNC), and Jesus 2012 (telomerase gene therapy extends lifespan without more cancer). Smoothing these into a 'tiered profile' violates the heterogeneity-preserving standard for evidence maps. (3) The Limitations section cites eight author-year sources not present in the source bundle, breaking auditability. (4) The single-source slices (Frailty, Dosing/PK, Longevity) cannot support class-level signal statements and should not be presented in the same table form as multi-source slices without explicit caveats. The Limitations and Tensions and Gaps sections are the strongest parts of the manuscript and correctly identify surrogate-endpoint, population-specificity, and mechanism-to-clinic gaps. Scope and search summary provide a generally auditable boundary, though search queries are generic. Recommendation: revise. The manuscript is salvageable with bounded edits — primarily (a) source-level attribution for each mapped finding, (b) honest surfacing of the directional disagreements already present in the bundle, and (c) reconciliation of the author-year/source-bundle mismatch. None of these require a scope reset.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis